Mladsi D, Zhou X, Mader G, Sanon M, Wang J, Barnett C, Willey C, Seliger S. Mortality risk in patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 2024 Feb 16;25(1):56. doi: 10.1186/s12882-024-03484-3
Danese D, Goss D, Romano (DeMuro) C, Gupta C. Qualitative assessment of the patient experience of primary hyperoxaluria type 1: an observational study. BMC Nephrol. 2023 Oct 26;24(1):319. doi: 10.1186/s12882-023-03365-1
Mader G, Mladsi D, Sanon M, Purser M, Barnett CL, Oberdhan D, Watnick T, Seliger S. A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease. BMC Nephrol. 2022 Oct 18;23(1):334. doi: 10.1186/s12882-022-02956-8
Willis SK, Mathew HM, Wise LA, Hatch EE, Wesselink AK, Rothman KJ, Mahalingaiah S. Menstrual patterns and self-reported hirsutism as assessed via the modified Ferriman-Gallwey scale: a cross-sectional study. Eur J Obstet Gynecol Reprod Biol. 2020 May 1;248:137-43. doi: 10.1016/j.ejogrb.2020.03.012
Nguyen Thi Nhan P, Van Toan D, Que Huong T, Minh Nguyet D, Thanh Dao T, Minh Tri L, Khac Minh T, Hoc TP Y. 3D-pharmacophore modeling and its application on allosteric inhibitors of rac serin/threonin protein kinase AKT1. Journal of Ho Chi Minh City Pharmacy Association. 2018;22(S1):380-8.
Rodríguez-Mías NL, Martínez-Franco E, Aguado J, Sánchez E, Amat-Tardiu L. Pelvic organ prolapse and stress urinary incontinence, do they share the same risk factors? Eur J Obstet Gynecol Reprod Biol. 2015 Jul;190:52-7. doi: 10.1016/j.ejogrb.2015.04.015
Williams RE, Kalilani L, DiBenedetti DB, Zhou X, Granger AL, Fehnel SE, Levine KB, Jordan J, Clark RV. Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United States. Climacteric. 2008 Jan 1;11(1):32-43.